Median overall survival (OS) of patients with combined immunotherapy showed a trend of prolongation (17.0 months 95% CI 12.9-21.13 vs . 11.6 months 95% CI 4.7-18.6), but no statistically significant difference was observed (p = 0.055).
← all excerpts
Treatment efficacy of first-line immunotherapy in advanced esophageal small cell carcinoma: A real-world retrospective study.
1
—
—